Nasdaq Panel grants Avenue Therapeutics extension to Oct 31 to meet equity requirement, Oct 6 for bid price

AVENUE THERAPEUTICS, INC.

Nasdaq Hearings Panel granted continued listing through Oct 31, 2022 to demonstrate compliance with stockholders' equity minimum of $2.5M.
Company must also satisfy minimum bid price of $1.00 per share by Oct 6, 2022.
Previously, Company was non-compliant with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
Hearing request on Aug 16, 2022 stayed suspension until Panel decision on Sep 29.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.